USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.
USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.
